Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Wai Conrad reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that executive Wai Conrad, CEO of Counterpart Health, received a grant of 267,766 shares of Class A common stock in the form of time-based restricted stock units. The award was granted at $0.00 per share, reflecting a compensation grant rather than a market purchase.
According to the vesting schedule, 25% of these RSUs will vest on the first anniversary of April 1, 2026, with the remaining units vesting in twelve equal quarterly installments beginning three months after that first anniversary, so that all RSUs are fully vested on April 1, 2030, subject to Mr. Conrad’s continued service. Following this grant, he holds 1,193,377 shares directly, and a family trust, for which he is a co-trustee, holds 1,610,482 shares indirectly.
Soares Karen reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments Chief Legal Officer Karen Soares received a grant of 382,522 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost and increase her direct ownership to 1,582,583 shares after the grant.
Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will then vest in twelve equal quarterly installments beginning three months after that first anniversary, with all RSUs fully vested on April 1, 2030, assuming she continues in service through each vesting date.
Clover Health Investments announced a planned transition in its finance leadership. Chief Financial Officer Peter Kuipers has stepped down from his roles as CFO, principal financial officer, and principal accounting officer, while remaining in an advisory capacity through April 24, 2026 to support the handoff.
The board appointed Clay Thornton, currently CFO of Clover’s insurance plan, as Interim Chief Financial Officer and principal financial officer, and named Joseph (Joe) Oldakowski as principal accounting officer. The company states that Kuipers’ departure does not reflect any disagreement on operations, policies, or practices, and it reiterates its most recently issued financial guidance for full year 2026.
Clover Health Investments Corp received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Clover Health common stock, representing 0% of the class.
The filing notes an internal realignment of Vanguard on January 12, 2026 and states certain subsidiaries will report separately in reliance on SEC Release No. 34-39538. The form is signed on March 26, 2026.
Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. The shares were sold in multiple trades between $1.87 and $1.96 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, Reynoso directly holds 2,716,735 Class A shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the proposed sale of 5,833 Restricted Stock Units on 03/14/2026. The filing also discloses prior 10b5-1 sales by Jamie Reynoso: 4,597 shares on 01/20/2026 and 2,102 shares on 01/07/2026, with reported dollar amounts of 11,871.75 and 5,319.32, respectively.
Clover Health Investments executive Jamie L. Reynoso reported automatic share withholdings to cover tax obligations tied to restricted stock units that vested on March 14 and 15, 2026. On March 14, 6,945 shares of Class A Common Stock were withheld at $1.98 per share, followed by 6,187 shares on March 15 at the same price. These are coded as tax-withholding dispositions rather than open-market sales. After the March 15 withholding, Reynoso directly holds 2,722,568 Class A shares.
The March 14 withholding relates to the final 6.25% vesting of time-based RSUs granted on March 14, 2022. The March 15 withholding relates to 6.25% of RSUs granted on September 16, 2022, which continue to vest quarterly in 6.25% installments through a final vesting date on September 15, 2026, subject to Reynoso’s continued service.
Clover Health Investments reported a routine tax-related share withholding by its General Counsel and Secretary, Karen Soares. On March 15, 2026, 4,528 shares of Class A common stock were automatically withheld to cover taxes when 6.25% of her September 15, 2022 time-based RSU grant vested. The remaining RSUs vest quarterly in 6.25% installments through September 15, 2026, subject to her continued service. After this withholding, she directly held 1,200,061 shares of Class A common stock.
Clover Health Investments, Corp. insider Conrad Wai, CEO of Counterpart Health, reported a routine tax-related share withholding. On March 14, 2026, 100,195 shares of Class A Common Stock were automatically withheld to cover tax obligations when the final 6.25% of his time-based RSUs granted on March 14, 2022 vested.
Following this tax-withholding disposition, Wai directly holds 925,611 shares of Class A Common Stock. He also has an indirect position of 1,610,482 shares held in a trust for his family's benefit, where he serves as co-trustee. The filing reflects compensation-related mechanics rather than an open-market sale.
Clover Health Investments, Corp. filed an amended report furnishing a supplemental shareholder Q&A that expands on its fourth quarter 2025 earnings communication. Management emphasizes that its 2026 guidance is anchored on achieving positive full-year GAAP net income, positioning this as proof of structural earnings power in its Medicare Advantage model.
The Q&A explains that strong member retention, a 4-Star payment year in 2026, cohort maturation, and deeper use of the Clover Assistant technology are expected to support improving unit economics. Clover describes its approach as focused on disciplined underwriting, operating leverage and medical cost performance rather than relying on favorable reimbursement changes.
The company also discusses pausing most broker commissions from January 1, 2026 outside selected New Jersey plans to prioritize onboarding quality and provider integration, outlines a strategy to improve Star Ratings, and highlights Counterpart Health as an asset-light, technology-driven platform built on Clover Assistant to help external partners manage risk and care more effectively over time.